Source comparison
What's the Half-Life of Tesamorelin: GHRH Analogue Comparison
Tesamorelin 26–43 minutes 2–3 hours Once daily GHRH receptor agonist with DPP-4 resistance Ideal for physiological pulsatile GH patterns without receptor desensitisation. Clinical data supports 52+ weeks continuous use Sermorelin 10–20 minutes 1.5–2 hours 1–2×
This comparison does not assign a generated winner or score.
- Tesamorelin
- 26–43 minutes
- 2–3 hours
- Once daily
- GHRH receptor agonist with DPP-4 resistance
- Ideal for physiological pulsatile GH patterns without receptor desensitisation. Clinical data supports 52+ weeks continuous use
- Sermorelin
- 10–20 minutes
- 1.5–2 hours
- 1–2× daily
- GHRH receptor agonist, minimal DPP-4 resistance
- Shorter action window requires more precise timing or split dosing; less forgiving than tesamorelin for meal proximity
- CJC-1295 (no DAC)
- 30 minutes
- GHRH receptor agonist with extended stability
- Functionally similar to tesamorelin; slightly longer half-life provides marginally wider injection window
- CJC-1295 with DAC
- 6–8 days
- Sustained elevation
- 1–2× weekly
- GHRH receptor agonist with albumin binding
- Convenient dosing but risks receptor downregulation and suppression of endogenous pulsatility with chronic use
- GHRP-2
- 20–30 minutes
- 1–2 hours
- 1–3× daily
- Ghrelin receptor agonist
- Often stacked with tesamorelin for synergistic GH release; acts on different pathway without extending half-life